In accordance with Section 3 of the Articles of Association of Orion Corporation, 520,144 A shares have been converted into 520,144 B shares. The conversion has been entered into the Trade Register on 2 June 2020.
The total number of shares in Orion Corporation is 141,257,828 which, after the conversion, consists of 35,507,125 A shares and 105,750,703 B shares. The number of votes of the company's shares is after the conversion 815,893,203.
SVP, Corporate Functions
Tuukka Hirvonen, Investor Relations, tel. +358 010 426 2721
Orionintie 1A, FI-02200 Espoo, Finland
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology, Finnish heritage rare diseases and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2019 amounted to EUR 1,051 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.